BREAKING: Lundbeck raises its full-year outlook as migraine drug Vyepti powers an earnings beat.
Danish drugmaker Lundbeck lifted 2026 revenue growth guidance to 11-12% at constant exchange rates, up from 7-9%, and adjusted EBITDA growth to 15-19%, up from 8-14%.
Nine-month revenue rose 13% CER to DKK 20.19 billion, with Vyepti sales up 45% CER to DKK 4.53 billion. Q3 adjusted EBITDA came in at DKK 2.26 billion, above the DKK 1.95 billion consensus, and shares rose around 5% to a record high.
Sources: Reuters, Lundbeck / PRNewswire (Nov 10, 2026)
#Lundbeck #Vyepti #Earnings #Stocks #Pharma #Markets
Danish drugmaker Lundbeck lifted 2026 revenue growth guidance to 11-12% at constant exchange rates, up from 7-9%, and adjusted EBITDA growth to 15-19%, up from 8-14%.
Nine-month revenue rose 13% CER to DKK 20.19 billion, with Vyepti sales up 45% CER to DKK 4.53 billion. Q3 adjusted EBITDA came in at DKK 2.26 billion, above the DKK 1.95 billion consensus, and shares rose around 5% to a record high.
Sources: Reuters, Lundbeck / PRNewswire (Nov 10, 2026)
#Lundbeck #Vyepti #Earnings #Stocks #Pharma #Markets
181 Views